H

Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627

Watchlist Manager
Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
Watchlist
Price: 4.01 CNY -4.3% Market Closed
Market Cap: 19.8B CNY
Have any thoughts about
Hubei Biocause Pharmaceutical Co Ltd?
Write Note

Hubei Biocause Pharmaceutical Co Ltd
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hubei Biocause Pharmaceutical Co Ltd
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
H
Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
Additional Paid In Capital
ÂĄ11B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
58%
China Life Insurance Co Ltd
SSE:601628
Additional Paid In Capital
ÂĄ53.9B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Ping An Insurance Group Co of China Ltd
SSE:601318
Additional Paid In Capital
ÂĄ134.4B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
4%
New China Life Insurance Company Ltd
SSE:601336
Additional Paid In Capital
ÂĄ24B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
S
Sunshine Insurance Group Co Ltd
HKEX:6963
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hubei Biocause Pharmaceutical Co Ltd
Glance View

Market Cap
19.8B CNY
Industry
Insurance

Hubei Biocause Pharmaceutical Co., Ltd. is an investment holding company that engages in the insurance industry. The company is headquartered in Jingmen, Hubei and currently employs 2,239 full-time employees. is a China-based company principally engaged in insurance business, such as life insurance, health insurance and casualty insurance. The firm is also involved in pharmaceutical business and chemical business. The Company’s products include polypropylene and Ibuprofen. The firm distributes its products in domestic market and to overseas markets, with Central China and South China as its main markets.

Intrinsic Value
4.79 CNY
Undervaluation 16%
Intrinsic Value
Price
H

See Also

What is Hubei Biocause Pharmaceutical Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
11B CNY

Based on the financial report for Jun 30, 2024, Hubei Biocause Pharmaceutical Co Ltd's Additional Paid In Capital amounts to 11B CNY.

What is Hubei Biocause Pharmaceutical Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
58%

Over the last year, the Additional Paid In Capital growth was -1%.

Back to Top